2-十八醇 | 593-32-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-十八醇
• 英文名称: 2-octadecanol
• 英文别名: octadecan-2-ol
• CAS: 593-32-8
• 化学式: C₁₈H₃₈O
• 分子量: 270.499
• InChiKey: OXGBCSQEKCRCHN-UHFFFAOYSA-N

物化性质

• 熔点：
  52°C
• 沸点：
  343.6°C (estimate)
• 密度：
  0.8473 (estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  19
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-十八醇 在 pyridinium dichromate 作用下， 生成 2-十八烷酮
  参考文献：
  名称：

  碲化氢钠可用作裂解环氧化物和季铵盐的亲核试剂

  摘要：

  碲化氢钠通过SN 2工艺干净地打开许多环氧化物，得到碲醇，通过用硼化镍还原可得到醇。通过在吡啶中用-甲苯-磺酰氯处理，将中间体碲醇以高产率转化为烯烃。季铵盐也可以被碲化氢钠有效地裂解。

  DOI：

  10.1016/s0040-4039(00)95051-2
• 作为产物：
  描述：

  2-十八烷酮 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 2-十八醇
  参考文献：
  名称：

  Breusch; Sokullu, Chemische Berichte, 1953, vol. 86, p. 681 Anm.

  摘要：

  DOI：

文献信息

• Certain substituted ureas, as modulators of kinase activity
  申请人：Mitchell A. Scott

  公开号：US20060270702A1

  公开（公告）日：2006-11-30

  Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

  本文提供了从化合物1的化学实体和药用可接受的盐、溶剂化合物、螯合物、非共价复合物和前药中选择的某些化学实体。本文还提供了包括至少一种化学实体和一种或多种药用可接受载体（如载体、辅料和赋形剂）的药物组合物。公开了治疗对血管生成激酶调节敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的有效量以减少疾病或疾病症状的方法。这些疾病包括癌症，包括乳腺肿瘤、子宫内膜癌、结肠癌和颈部鳞状细胞癌。治疗方法包括将至少一种化学实体作为单一活性剂或将至少一种化学实体与一种或多种其他治疗剂结合使用的方法。一种用于确定样品中是否存在血管生成激酶的方法，包括将样品与至少一种化学实体接触在允许检测血管生成激酶活性的条件下，检测血管生成激酶活性水平，并从中确定样品中是否存在血管生成激酶。
• [EN] TRPV4 RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR DU TRPV4
  申请人：UNIV UTAH RES FOUND

  公开号：WO2021102314A1

  公开（公告）日：2021-05-27

  Described are receptor ligands of transient receptor potential cation channel subfamily V member 4 (TRPV4), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ocular disorders.

  描述了转瞬性受体电位阳离子通道亚家族V成员4（TRPV4）的受体配体，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗眼部疾病的方法。
• [EN] BORON-CONTAINING RHO KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA RHO KINASE CONTENANT DU BORE
  申请人：PERCIPIAD INC

  公开号：WO2021011873A1

  公开（公告）日：2021-01-21

  The present invention provides boron-containing isoquinoline compounds as protein kinase-modulating compounds. These compounds are useful as neuroprotective and neuro-regenerative agents for the amelioration of glaucoma and other ocular neuropathies.

  本发明提供了含硼的异喹啉化合物作为蛋白激酶调节化合物。这些化合物可用作神经保护和神经再生剂，用于改善青光眼和其他眼神经病变。
• [EN] CERTAIN HETEROCYCLIC SUBSTITUTED IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHODS OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS<br/>[FR] CERTAINES IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES SUBSTITUEES HETEROCYCLIQUES ET METHODES D'INHIBITION DE LA TYROSINE KINASE DE BRUTON UTILISANT CES COMPOSES
  申请人：CELLULAR GENOMICS INC

  公开号：WO2005005429A1

  公开（公告）日：2005-01-20

  Compounds of formula (I) and all pharmaceutically acceptable forms thereof, are described herein. The variables R1, R2, R3, Z2, and Q, shown in Formula I are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction. Thus methods of treatment include administering a sufficient amount of a compound or salt as provided herein to decrease the symptoms or slow the progression of these diseases. Other embodiments include methods of treating other animals, including livestock and domesticated companion animals, suffering from a disease responsive to inhibition of kinase activity. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent. A method for determining the presence of Btk in a sample, comprising contacting the sample with a compound or form thereof of Formula I under conditions that permit detection of Btk activity, detecting a level of Btk activity in the sample, and therefrom determining the presence or absence of Btk in the sample.

  公式(I)的化合物及其所有药物可接受的形态在此描述。公式I中所示的变量R1、R2、R3、Z2和Q在此定义。提供含有公式I的一个或多个化合物，或此类化合物的药物可接受的形态，以及一个或多个药物可接受的载体、辅料或稀释剂的药物组合物。还提供了治疗对抑制酪氨酸激酶活性有反应的某些疾病患者的方法。在某些实施例中，这些疾病对抑制Btk活性和/或B细胞增殖有反应。这些方法包括向患者给药公式I的化合物，以减少疾病的迹象或症状。这些疾病包括癌症、自身免疫和/或炎症性疾病，或急性炎症反应。因此，治疗方法包括给药足够量的本处提供的化合物或盐，以减少这些疾病的症状或减缓这些疾病的进展。其他实施例包括治疗其他动物的方法，包括家畜和驯养的伴侣动物，这些动物患有一种对抑制激酶活性有反应的疾病。治疗方法包括将公式I的化合物作为单一活性剂给药，或将公式I的化合物与一个或多个其他治疗剂组合给药。一种用于确定样本中Btk存在的方法，包括在允许检测Btk活性的条件下将样本与公式I的化合物或其形态接触，检测样本中的Btk活性水平，并据此确定样本中Btk的存在或不存在。
• [EN] ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS<br/>[FR] ANTI-INFECTIEUX A BASE D'ISOTHIAZOLOQUINOLONES ET DE SELS CORRESPONDANTS
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2005019228A1

  公开（公告）日：2005-03-03

  The invention provides compounds and salts of Formula (I) and Formula (II): which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula (I) and Formula (II). The variables A1, R2, R3, R5, R6, R7, A8 and R9 are defined herein. Certain compounds of Formula (I) and Formula (II) disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula (I) or Formula (II) and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula (I) or Formula (II) as the only active agent or may contain a combination of a compound of Formula (I) or Formula (II) and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

  本发明提供了具有抗菌活性的公式(I)和公式(II)的化合物及盐类：本发明还提供了用于制造公式(I)和公式(II)化合物的新的合成中间体。变量A1、R2、R3、R5、R6、R7、A8和R9在此文中定义。本文披露的某些公式(I)和公式(II)化合物是细菌DNA合成和细菌复制的强效和选择性抑制剂。本发明还提供了含有一种或多种公式(I)或公式(II)化合物以及一种或多种载体、辅料或稀释剂的抗菌组合物，包括药物组合物。这样的组合物可以只含有公式(I)或公式(II)的化合物作为唯一的活性成分，也可以含有公式(I)或公式(II)的化合物与一种或多种其他活性成分的组合。本发明还提供了用于治疗动物微生物感染的方法。